All In Biotech

Drug Trial Radar · NCT03675893

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer

RESOLVE: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin and Gedatolisib

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Dec 24, 2018

Primary completion

Aug 1, 2028

Study completion Aug 1, 2031

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eli Lilly and Company; Celcuity Inc
First posted
Sep 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (also known as Glucophage®) * Gedatolisib (also known as PF-05212384)

Conditions

  • Endometrial Cancer

Interventions

  • LetrozoleDrug

    Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.

  • AbemaciclibDrug

    Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.

  • LY3023414Drug

    LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.

  • MetforminDrug

    Metformin inhibits mitochondrial adenosine-5'-triphosphate (ATP) synthesis, resulting in activation of the AMPK (5' AMP-activated protein kinase) pathway through LKB1, eventually causing inhibition of the mTOR pathway and subsequent reduction in protein synthesis and cellular proliferation.

  • GedatolisibDrug

    Gedatolisib is a PI3K/AKT/mTOR (PAM) pathway inhibitor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival RateTime frame: 6 months
  2. Objective Tumor Response RateTime frame: 6 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.